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Background. Case series of patients with a diagnosis of thrombotic thrombocytopenic purpura (TTP) have
reported different frequencies of human immunodeficiency virus (HIV) infection; some series suggest that HIV
infection may cause TTP.
Methods. We systematically reviewed all reports of HIV infection in case series of patients with TTP. We
analyzed data from the Oklahoma TTP-HUS (hemolytic uremic syndrome) Registry, an inception cohort of 362
consecutive patients, for 1989–2007.
Results. Nineteen case series reported the occurrence of HIV infection at the time of diagnosis of TTP in 0%–
83% of patients; individual patient data were rarely described. The Oklahoma TTP-HUS Registry determined the
HIV status at the time of diagnosis of TTP in 351 (97%) of 362 patients. HIV infection was documented in 6
(1.84%; 95% CI, 0.68%–4.01%) of 326 adult patients (age, 26–51 years); follow-up data were complete for all 6
patients. The period prevalence of HIV infection among all adults in the Oklahoma TTP-HUS Registry region for
1989–2007 was 0.30%. One patient had typical features of TTP with 5 relapses. Five patients had single episodes;
in 4, the clinical features that had initially suggested the diagnosis of TTP were subsequently attributed to malignant
hypertension (in 3 patients) and disseminated Kaposi sarcoma (in 1 patient).
Conclusions. HIV infection, similar to other inflammatory conditions, may trigger acute episodes of TTP in
susceptible patients. More commonly, acquired immunodeficiency syndrome–related disorders may mimic the
clinical features of TTP. If the diagnosis of TTP is suggested in a patient with HIV infection, there should be
careful evaluation for alternative diagnoses and cautious consideration of plasma exchange, the required treatment
for TTP.
Soon after the first reports of AIDS, there were reports
of thrombotic thrombocytopenic purpura (TTP) in pa-
tients with HIV infection, suggesting that TTP was a
“new manifestation of infection with HIV” [1, p. 195].
Recent case series of TTP that reported a high frequency
of patients who also had HIV infection have suggested
that HIV-associated TTP is a specific entity [2–5], that
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HIV infection can cause TTP [6–8], and that TTP may
be an AIDS-defining disorder [9]. However, a different
interpretation, based on analysis of 350 consecutive
hospitalized patients with HIV infection, was that the
characteristic clinical features of TTP, microangiopathic
hemolytic anemia, thrombocytopenia, and abnormal
renal function, were manifestations of advanced HIV
infection [10]. These different perspectives reflect the
fact that the diagnosis of TTP is often uncertain, es-
pecially in patients with other complex medical prob-
lems, because of the absence of specific diagnostic cri-
teria for TTP [11].
In patients with TTP, the only consistent abnormal-
ities are microangiopathic hemolytic anemia, which is
defined by schistocytes (fragmented RBCs on the pe-
ripheral blood smear) and a negative direct antiglobulin
Table 1. Case series of patients with thrombotic thrombocytopenic purpura (TTP) that report the occurrence of HIV infection.
Case series Location
Patient
accrual period
No. of
patients
with TTP
No. (%) of
patients with
TTP and
HIV infection
No. (%) of
patients with TTP
who were
tested for
HIV infection
Authors’ comments and
interpretation
Leaf et al. [1]a New York, NY 1980–1987 14 4 NR Report “established TTP
as a new manifestation
of infection with HIV”
(p. 195)
Thompson et al. [16]a San Francisco, CA 1980–1991 44 7 NR Reports “suggested a
possible relationship be-
tween TMA and HIV”
(p. 1894)
Ucar et al. [17]a Miami, FL 1979–1991 50 11 (22) 50 (100) “HIV infection appears to
be associated with
TMA” (p. 304)
Hayward et al. [18] Toronto, Ontario, Canada 1977–1988 52 0 NR 1 Patient had transfusion-
acquired HIV infection,
which probably occurred
after TTP
Dawson et al. [19] Baltimore, MD NR 50 0 NR 1 Patient became HIV in-
fected after receiving
PEX for TTP
Tsai et al. [20] New York, NY NR 37 2 NR No comments about HIV
infection
Lara et al. [21] Sacramento, CA 1978–1998 126 6 NR HIV infection reported as
a “comorbid condition”
(p. 575)
Dervenoulas et al. [22] Athens, Greece 1985–1998 48 0 (0) 48 (100) No comments about HIV
infection
Haas et al. [23] Vienna, Austria 1992–2000 30 1 NR HIV infection reported as
a “TTP/HUS associated
condition” (p. 416)
Chang et al. [24] Dayton, OH 1981–2000 74 2 NR HIV infection reported as
“significant underlying
pathology” (p. 203)
Tostivint et al. [2] and
Maslo et al. [27]
Paris, France 1990–1998 55 18 NR AIDS-associated HUS re-
ported as a specific en-
tity; 8 (44%) of 18 pa-
tients with HIV infection
had CMV infection
Coppo et al. [25] Paris, France NR 30 9 NR 8 (89%) Of 9 patients
with HIV infection had
an acute bacterial infec-
tion; selected from in-
tensive care unit
patients
Kremer Hovinga et al. [26] Berne, Switzerland 1997–2003 396 1 NR Report from a reference
laboratory testing
ADAMTS13 activity with
limited clinical data
Pene et al. [6] Paris, France 1998–2001 63 13 NR HIV infection reported as
an “etiology or favoring
condition” (p. 74)
Miller et al. [3]a London, England 1998–2004 64 8 NR “HIV-associated TTP” is
“a rare cause of throm-
bocytopenia in patients
with HIV” (p. 542)
Novitzky et al. [4]a Cape Town, South
Africa
1996–2003 44 21 (48) 44 (100) Comparative study of
patients with “classic
TTP” and patients with
“HIV infection–related
TTP” (p. 374)
Outschoorn et al. [7] Philadelphia, PA 1984–2004 61 8 NR HIV infection reported as
an “etiology” of TTP (p.
897)
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Table 1. (Continued.)
Case series Location
Patient
accrual period
No. of
patients
with TTP
No. (%) of
patients with
TTP and
HIV infection
No. (%) of
patients with TTP
who were
tested for
HIV infection
Authors’ comments and
interpretation
Tuncer et al. [5] Birmingham, AL 1996–2004 90 6 NR HIV infection reported as
an “associated condi-
tion” of TTP (p. 109)
Gunther et al. [8]a Johannesburg, South
Africa
2003–2005 24 20 (83) 24 (100) HIV infection “is now by
far the commonest
cause of TTP” (p. 1711)
Current report Oklahoma 1989–2007 362 (all patients);
336 (adults)
6 (1.7) of 351;
6 (1.8) of 326
351 (97); 326 (97) In 4 patients with HIV in-
fection, the presenting
features were subse-
quently attributed to an-
other diagnosis
NOTE. CMV, cytomegalovirus; HUS, hemolytic uremic syndrome; NR, not reported; PEX, plasma exchange treatment; TMA, thrombotic microangiopathy.
a These citations were identified by the keyword search; these articles describe 10 patients and specifically addressed the association of HIV infection and
TTP.
test result, and thrombocytopenia—features that can occur in
other conditions. Severely deficient activity of ADAMTS13, a
plasma von Willebrand–cleaving protease, caused by autoan-
tibody inhibition is characteristic of TTP and was initially
thought to be diagnostic of TTP [12]. However, measurements
of ADAMTS13 activity are not sufficiently sensitive or specific
to consistently distinguish TTP from other severe systemic dis-
orders [11].
To investigate the association of HIV infection and TTP, we
had 4 objectives. First, to provide a comprehensive background,
we systematically reviewed case series of patients with TTP to
document the reported frequency of HIV infection. Second, to
describe our experience of HIV infection among patients who
have received a diagnosis of TTP, we analyzed data from the
Oklahoma TTP-HUS (hemolytic uremic syndrome) Registry,
an inception cohort of all 362 consecutive patients with an
initial episode of clinically diagnosed TTP within a defined
geographic region in 1989–2007 [13, 14]. Third, to interpret
our experience, we compared the frequency of HIV infection
among registry patients with the prevalence of HIV infection
among all adults in the registry region. Fourth, to determine
possible reasons for an association of HIV infection and TTP,
we analyzed the clinical course and continuous follow-up of
each patient in the registry who had HIV infection at the time
of his or her diagnosis of TTP.
METHODS
Systematic literature review. OVID software was used to
search the Medline database on 30 May 2008. Articles con-
taining both a keyword or medical subject heading in the title
or available text for TTP (“thrombotic thrombocytopenic pur-
pura,” “TTP,” “hemolytic-uremic syndrome,” “HUS,” “throm-
botic thrombocytopenic purpura–hemolytic uremic syn-
drome,” “TTP-HUS,” “thrombotic microangiopathy,” “TMA,”
“microangiopathy,” “intravascular hemolysis,” and “plasma ex-
change”) and also for HIV (“human immunodeficiency virus,”
“HIV,” “acquired immunodeficiency syndrome,” and “AIDS”)
were identified. Case series involving 10 patients with TTP
that reported data on the presence or absence of HIV infection
were selected for review. The bibliographies of the selected ar-
ticles were searched to identify additional articles.
To search for additional articles that may have reported HIV
infection, we identified all case series involving 25 patients
with TTP published since 1981 by reviewing the titles and
relevant abstracts of English-language articles that were re-
trieved by the search terms “thrombotic thrombocytopenic
purpura” and “TTP.”
Oklahoma TTP-HUS Registry patients. The Oklahoma
TTP-HUS Registry includes data on all consecutive patients for
whom the Oklahoma Blood Institute was requested to provide
plasma exchange treatment for patients with a diagnosis of TTP
or HUS since 1 January 1989 [13, 14]. The Oklahoma Blood
Institute is the sole provider of plasma exchange services for
all hospitals in 58 of the 77 Oklahoma counties. Because the
standard practice in this region is to treat all adult patients who
have received a diagnosis of either TTP or HUS with plasma
exchange, the registry is an inception cohort of consecutive
patients for whom a diagnosis of TTP or HUS was made and
for whom plasma exchange treatment was requested. Because
these syndromes in adults are commonly known as TTP [11],
we describe patients in this report as having TTP. Serum sam-
ples were obtained for HIV testing and ADAMTS13 assays
immediately before the first plasma exchange; ADAMTS13 ac-
tivity and its inhibition were measured by previously described
methods [12, 15]. Deficiency of ADAMTS13 was defined as
activity of !10% [14]. The Oklahoma TTP-HUS Registry is
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Table 2. Clinical categories of 326 adult patients with a clin-
ical diagnosis of thrombotic thrombocytopenic purpura in the
Oklahoma TTP-HUS (hemolytic uremic syndrome) Registry, 1989–
2007.
Clinical category
No. of patients
HIV negative
(n p 320)
HIV positive
(n p 6)
HSCT 21 0
Pregnancy 23 0
Drug associated 42 0
Bloody-diarrhea prodrome 22 0
Additional or alternative diagnoses
Sepsis 26 0
Disseminated malignancy 11 1
Autoimmune disorder 34 0
Malignant hypertension 3 3
Multiorgan failure 10 0
Idiopathic 128 2
NOTE. These categories, as previously defined [13], represent associated
conditions and potential etiologies. Patients are assigned to one of these
categories in sequential, hierarchical order (from top to bottom in this table)
on the basis of their initial episode of thrombotic thrombocytopenic purpura
[13]. HSCT, hematopoietic stem cell transplantation.
approved by the institutional review boards of the University
of Oklahoma Health Sciences Center and each participating
hospital.
Prevalence of HIV infection in the Oklahoma TTP-HUS
Registry region. Data regarding the cumulative frequency of
people with HIV infection who are currently or were living in
each county of Oklahoma during 1989–2007 were available
from the Oklahoma State Department of Health. We limited
our analysis to adults (age, 20 years), because the patients in
the Oklahoma TTP-HUS Registry with HIV infection were all
adults and because the prevalence of HIV infection was much
lower among children. To calculate period prevalence for 1989–
2007, we used 2000 US Census data for population estimates
for each of the 58 counties of the registry region.
RESULTS
Systematic literature review. The keyword search retrieved
78 articles; 7 retrospective case series involving 10 patients
with a diagnosis of TTP were identified that specifically de-
scribed the presence of HIV infection [1–4, 8, 16, 17]. The
search terms “thrombotic thrombocytopenic purpura” and
“TTP” retrieved 3317 articles; 65 additional retrospective case
series published after 1981 that described 25 patients were
identified: 43 (66%) did not mention HIV infection, 10 (15%)
specifically excluded patients with HIV infection, and 12 (19%)
[5–7, 18–26] described the presence (9 articles) or absence (3
articles) of patients with HIV infection at the time of diagnosis
of TTP. These 19 case series are presented in table 1. In 4 articles,
all patients were tested for HIV, and the reported frequencies
of HIV infection were 0% [22], 22% [17], 48% [4], and 83%
[8]. In the other 15 articles, the number of patients tested for
HIV infection was not reported. Most articles described HIV
infection as an associated condition or cause of TTP. Only 2
studies presented individual patient data [2, 17, 27]. In 1 article
[17], 3 of 4 patients with HIV infection had potential causes
other than TTP for their clinical features: malignant hyperten-
sion [28], sepsis [14], and cocaine intoxication [29]. Eight
(44%) of 18 patients in the other study had cytomegalovirus
infection [2, 27].
Oklahoma TTP-HUS Registry patients. The Oklahoma
TTP-HUS Registry enrolled 362 patients with an initial episode
of clinically diagnosed TTP during 1989–2007. Tests for HIV
infection were performed for 351 patients (97%); HIV infection
was documented in 6 patients (age, 26–51 years) at the time
of their initial diagnoses of TTP. All 6 patients have been con-
tinuously followed up to the present time or until death. Be-
cause all patients with HIV infection were adults, all subsequent
analyses were limited to adult patients. The period prevalence
of HIV infection during 1989–2007 among the 326 adult pa-
tients (age, 20 years) who were tested for HIV was 1.84%
(95% CI, 0.68%–4.01%) [30]. The period prevalence of HIV
infection during 1989–2007 among all adults aged 20 years
in the 58 counties of the registry region was 0.30%.
Table 2 describes the 326 adult patients in the Oklahoma
TTP-HUS Registry according to clinical categories based on
their associated conditions and additional or alternative diag-
noses [13]. One hundred thirty patients are described as idi-
opathic because they had none of the conditions that define
the other categories. Two of the patients in the idiopathic cat-
egory were HIV positive. In 6 patients, the clinical features that
had initially suggested the diagnosis of TTP were subsequently
attributed to malignant hypertension; 3 were HIV positive. Dis-
seminated malignancy was diagnosed in 12 patients after
plasma exchange treatment for TTP was begun; 1 was HIV
positive.
Among the 236 adult patients who were enrolled in the reg-
istry since 13 November 1995, when routine testing for
ADAMTS13 activity was begun, and who were also tested for
HIV infection, ADAMTS13 activity was measured in 226
(96%). Among the 220 HIV-negative patients, ADAMTS13 de-
ficiency was present in 38 (46%) of 82 idiopathic patients and
12 (9%) of 138 patients in other clinical categories. ADAMTS13
activity was measured in all 6 HIV-positive patients. In 2 pa-
tients, ADAMTS13 activity was deficient (!10%): 1 with typical
relapsing TTP (patient 1, table 3) and 1 whose final diagnosis
was disseminated Kaposi sarcoma (patient 4). ADAMTS13 ac-
tivity was 12% in the other patient (patient 3) in the idiopath-
ic category and 45%-65% in the 3 patients whose presenting
clinical features were subsequently attributed to malignant
hypertension.
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Table 4. Clinical features in patients presenting with thrombocytopenia and anemia that are uncommon in thrombotic thrombo-
cytopenic purpura (TTP) and suggest an alternative diagnosis.
Clinical features that are uncommon in patients with TTP Possible alternative diagnoses
Systemic symptoms
Fever (temperature, 138.8C [102F]), shaking chills, and
myalgias
Sepsis
Severe hypertension (blood pressure, 1200/120 mm Hg) with
retinopathy (flame hemorrhages, papilledema)
Malignant hypertension with renal thrombotic microangiopathy
Hematopoietic system
Disseminated intravascular coagulation (low plasma fibrinogen
level, prolonged prothrombin time, and activated partial throm-
boplastin time)
Sepsis, disseminated malignancy
Systemic, confluent purpuric or ecchymotic rash, and ischemic
digits
Sepsis
Neutropenia Sepsis, drug toxicity
Peripheral blood smear findings
Nucleated RBCs and immature granulocytes Marrow infiltration with tumor or granulomatous disease
Oval macrocytes and neutropenia Megaloblastic anemia (vitamin B12 or folate deficiency)
Vascular system: arterial or venous thrombosis Heparin-induced thrombocytopenia and thrombosis
Pulmonary system
Pulmonary infiltrate Infection or malignancy
Cough with hemoptysis Malignancy
Liver and biliary system: jaundice with high conjugated bilirubin Toxic or infectious hepatic failure, malignancy
Neurologic system: stiff neck Meningitis
The clinical courses of the 6 HIV-positive patients are pre-
sented in table 3. Patients 1 and 3 were assigned to the idio-
pathic category in table 2. Patient 1 had characteristic clinical
features of TTP and responded promptly to plasma exchange
treatment. HIV infection was discovered incidentally at the time
of TTP diagnosis and progressed to AIDS (defined on the basis
of a CD4 cell count of 154 cells/mL). He was not compliant
with prescribed HAART. During 9 years, he had 6 episodes of
TTP with no apparent preceding infectious or other illnesses.
ADAMTS13 deficiency was present in his last 3 episodes. After
recovery from his last episode of TTP, he died at home; an
autopsy revealed systemic infection with gram-positive cocci
and no evidence of recurrent TTP.
Patient 3 had been ill for 6 months with fever and weight
loss. AIDS was diagnosed 3 weeks before his diagnosis of TTP,
when he developed esophageal candidiasis. Treatment was be-
gun with zidovudine, lamivudine, efavirenz, and fluconazole.
He was hospitalized for repeated seizures, became comatose,
and required intubation. CT demonstrated cerebral atrophy
consistent with HIV encephalopathy. Coagulation studies sug-
gested disseminated intravascular coagulation. When there was
no evidence of sepsis, plasma exchange treatment for TTP was
begun but was stopped when there was no clinical or hema-
tologic response. Three days after stopping plasma exchange,
the patient regained consciousness and subsequently recovered.
Although coagulation abnormalities, lack of response to plas-
ma exchange treatment, and recovery after plasma exchange
treatment was stopped were not typical of TTP, no alternative
diagnosis was discovered. Currently, he is doing well with
HAART.
In the other 4 patients, the clinical features that had initially
suggested the diagnosis of TTP (thrombocytopenia, anemia
with schistocytes, and acute renal failure) were subsequently
attributed to other conditions. Patient 4 had been diagnosed
as having AIDS 2 weeks previously and began treatment with
lamivudine, tenofovir, and efavirenz. Chest radiography dem-
onstrated pulmonary infiltrates; plasma exchange for TTP was
begun when evaluation for Pneumocystis species yielded neg-
ative results. He subsequently developed violaceous papules on
both legs. Plasma exchange was stopped because of no response,
and he died 5 days later. Autopsy demonstrated disseminated
Kaposi sarcoma; thrombotic microangiopathy characteristic of
TTP was not present. In the other 3 patients, the clinical features
were subsequently attributed to malignant hypertension; none
responded to plasma exchange treatment. Patient 2 had pro-
gressive weakness for 4 months. HIV infection was diagnosed
during routine testing at the time of TTP diagnosis. A renal
biopsy specimen demonstrated diffuse sclerosing glomerulo-
pathy consistent with HIV-associated nephropathy with no
thrombotic microangiopathy. The patient developed progres-
sive multifocal leukoencephalopathy and died 10 months after
the diagnosis of HIV/AIDS. Patient 5 had progressive weakness
for 2 months. He had severe hypertension and bilateral small
kidneys. HIV infection was diagnosed during routine testing at
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Table 5. Possible reasons why patients with HIV infection may
be diagnosed as having thrombotic thrombocytopenic purpura
(TTP).
Inflammatory disorders may trigger an acute episode of TTP in a
susceptible patient, such as a patient with ADAMTS13
deficiency
Infection (HIV infection itself or an opportunistic infection)
Immune reconstitution with response to HAART
AIDS-related disorders may mimic TTP
Opportunistic, angioinvasive infections (e.g., CMV or HHV-8
infection)
Disseminated malignancy
HIV-associated nephropathy with malignant hypertension
HIV-induced endothelial injury may cause thrombotic
microangiopathy
The occurrence of TTP in a patient with HIV infection may be
coincidental
NOTE. CMV, cytomegalovirus; HHV-8, human herpesvirus 8.
the time of TTP diagnosis. He continues to require hemodi-
alysis. He has never taken treatment for HIV infection. Patient
6 had progressive weakness and weight loss for 3 months before
her TTP diagnosis. She had received a diagnosis of AIDS 11
years previously and had received HAART for the initial 6 years,
but then received no antiretroviral treatment for the next 5
years. She had bilateral pulmonary infiltrates attributed to con-
gestive heart failure. A renal biopsy specimen demonstrated
end-stage renal disease with thrombotic microangiopathy at-
tributed to malignant hypertension. She continues to undergo
hemodialysis without treatment for her HIV infection.
DISCUSSION
Although most case series of patients with TTP do not mention
HIV infection, some have reported a high frequency of HIV
infection among patients diagnosed as having TTP and have
suggested that it may cause TTP [6–8]. However, the disparity
of reported frequencies of HIV infection among patients who
have received a diagnosis of TTP is great (0%–83%) [4, 8, 17,
22]. The reports describing the highest frequency of HIV in-
fection among patients diagnosed as having TTP (48% [4] and
83% [8]) may reflect the high regional prevalence of HIV in-
fection among the population of South Africa [31]. Other re-
ports describing HIV infection among patients in whom TTP
has been diagnosed are from hospitals that may also serve
populations with a high prevalence of HIV infection (table 1).
The lack of individual patient data and follow-up in these re-
ports limits the ability to interpret the relationship between
HIV infection and the clinical features suggesting TTP. The
reports that describe individual patient data suggest the pos-
sibility that other disorders may have caused these clinical fea-
tures [2, 17, 27]. Because diagnostic criteria for TTP, requiring
only the presence of microangiopathic hemolytic anemia and
thrombocytopenia with no alternative cause [11], are not spe-
cific, and because AIDS-related disorders may cause these ab-
normalities [10], the diagnosis of TTP is often uncertain in
patients with HIV infection.
Although TTP is characterized by systemic microvascular
thrombosis that may cause abnormalities of multiple organ
systems, some clinical features are uncommon and suggest al-
ternative diagnoses (table 4). The critical initial clinical decision
is whether to initiate plasma exchange—the specific treatment
for TTP but also a procedure with a high risk of serious com-
plications. A prospective analysis of 206 consecutive patients
treated with plasma exchange for TTP documented that 57
patients (28%) had 75 major complications; 5 patients (2.4%)
died of these complications: 3 died of complications of central
venous catheter insertion, and 2 died of sepsis attributed to
the indwelling central venous catheter [32].
ADAMTS13 deficiency is a characteristic abnormality of TTP
[14]. However, the interpretation of ADAMTS13 activity levels
among our 6 patients with HIV infection was uncertain. Patient
1, who had typical relapsing TTP, had normal ADAMTS13
activity in his first episode before becoming deficient as a result
of an inhibitor in later episodes. Patient 4, with disseminated
Kaposi sarcoma but no evidence of TTP at autopsy, also had
ADAMTS13 deficiency with an inhibitor. ADAMTS13 activity
was 12% with a demonstrable inhibitor in patient 3, who was
considered to have idiopathic TTP despite atypical clinical fea-
tures. The 3 patients whose presenting features were subse-
quently attributed to malignant hypertension had normal
ADAMTS13 activity. These data suggest that, among HIV-
infected patients, ADAMTS13 activity measurements cannot
distinguish patients with typical TTP from patients whose clin-
ical features were subsequently attributed to another diagnosis.
Although the frequency of alternative diagnoses among HIV-
positive patients is greater than among HIV-negative patients,
similar alternative diagnoses occurred [28, 33].
The period prevalence of HIV infection among patients in
the Oklahoma TTP-HUS Registry (1.84%; 95% CI, 0.68%–
4.01%) was low compared with many published case series but
was greater than the period prevalence of HIV infection among
adults in the registry region (0.30%). The higher prevalence of
HIV infection among patients with a diagnosis of TTP may be
related to the fact that the presenting clinical features in 4 of
the 6 patients were subsequently attributed to AIDS-related
disorders. Also, HIV testing was not performed for all indi-
viduals in the registry region population, resulting in the es-
timate that 25% of patients living with HIV infection in the
United States have undiagnosed conditions [34]. In contrast,
HIV testing was performed for 97% of patients in the registry.
There may be multiple reasons why patients with HIV in-
fection are diagnosed as having TTP (table 5). First, HIV in-
fection, AIDS-related disorders, or treatment-induced immune
reconstitution [35] may trigger episodes of TTP in susceptible
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patients. This sequence is similar to observations that infections
[36], inflammatory conditions [37], and pregnancy [38] can
trigger episodes of TTP in patients without HIV infection. This
could have been the basis for the association of HIV infection
with TTP in patient 1. Second, AIDS-related disorders can
mimic the clinical features of TTP; this was the conclusion for
patients 2, 4, 5, and 6.
Third, there may be a specific entity of HIV-associated
thrombotic microangiopathy [39], suggested by observations
of endothelial dysfunction with deposition of thrombi in the
vessel wall [40]. Human herpesvirus 8 infection, which is com-
mon among HIV-infected patients, involves vascular endothe-
lial cells and may contribute to development of thrombotic
microangiopathy [41]. Analogous to HIV-associated throm-
botic microangiopathy, transplantation-associated thrombotic
microangiopathy, a syndrome that occurs after allogeneic he-
matopoietic stem cell transplantation and may result from con-
ditioning regimen toxicity, graft-versus-host disease, and in-
fections [42], was also previously considered to be TTP and
therefore was treated with plasma exchange. Transplantation-
associated thrombotic microangiopathy is now considered to
be a specific entity, distinct from TTP, for which plasma ex-
change treatment is not appropriate [43]. Describing HIV-
associated thrombotic microangiopathy as a specific entity
could help to avoid plasma exchange treatment in HIV-infected
patients whose clinical features are not typical of TTP [39].
HIV-associated thrombotic microangiopathy and AIDS-re-
lated disorders that may mimic TTP occur in patients with
more advanced HIV infection [10, 44]. This finding is consis-
tent with observations of decreased frequency of the diagnosis
of TTP among patients with HIV infection during the HAART
era [39, 45, 46]. The ability of HAART to down-regulate in-
flammation may also contribute to the decreased development
of thrombotic microangiopathy [47]. Four of our 6 HIV-
infected patients (patients 2, 3, 4, and 6) had AIDS-defining
criteria documented before or at the time of their diagnosis of
TTP; none had received HAART except for patient 6, and she
had not been treated for 5 years.
Strengths of this study are the inception cohort of all 362
consecutive patients with an initial episode of clinically diag-
nosed TTP in a defined geographic region across 19 years, the
documentation of the presence or absence of HIV infection in
97% of these patients, and analysis of the clinical course with
complete follow-up of the 6 patients with HIV infection. Lim-
itations are the small number of patients with HIV infection,
their complex illnesses, and the nonspecific diagnostic criteria
for TTP.
Although HIV infection and AIDS-related disorders may
trigger acute episodes of TTP, similar to other infections and
inflammatory disorders, our experience does not support the
existence of HIV-associated TTP as a specific entity or the
hypothesis that HIV infection can cause TTP. If the diagnosis
of TTP is suggested in a patient with HIV infection, there
should be careful evaluation for alternative origins in addition
to appropriate treatment of the HIV infection. Treatment with
plasma exchange must be considered cautiously.
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